{
  "prefix": {
    "pe": "https://proofengine.info/proofs/daily-low-dose-aspirin-reduces-the-risk-of-recurrent-non-fatal-myocardial/",
    "prov": "http://www.w3.org/ns/prov#",
    "xsd": "http://www.w3.org/2001/XMLSchema#",
    "schema": "http://schema.org/"
  },
  "entity": {
    "pe:claim": {
      "prov:type": "pe:Claim",
      "prov:label": "Daily low-dose aspirin reduces the risk of recurrent non-fatal myocardial infarction in patients with prior cardiovascular disease, per the Antithrombotic Trialists' Collaboration meta-analysis.",
      "prov:value": "Daily low-dose aspirin reduces the risk of recurrent non-fatal myocardial infarction in patients with prior cardiovascular disease, per the Antithrombotic Trialists' Collaboration meta-analysis."
    },
    "pe:evidence-B1": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "SC1 - ATT 2002 BMJ: non-fatal MI reduced by one third in high-risk patients",
      "pe:factId": "B1",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC64503/",
      "pe:sourceName": "Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 (full text via PubMed Central, PMC64503)."
    },
    "pe:evidence-B2": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "SC1 - ATT 2002 BMJ: low-dose aspirin (75-150 mg) at least as effective as higher doses",
      "pe:factId": "B2",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC64503/",
      "pe:sourceName": "Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 (full text via PubMed Central, PMC64503)."
    },
    "pe:evidence-B3": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "SC1 - ATT 2009 Lancet: aspirin reduces serious vascular events in secondary-prevention trials",
      "pe:factId": "B3",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/19482214/",
      "pe:sourceName": "Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60 (abstract via PubMed, PMID 19482214)."
    },
    "pe:evidence-B4": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "SC2 - ATT 2002 BMJ: inclusion restricted to randomised trials",
      "pe:factId": "B4",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pmc.ncbi.nlm.nih.gov/articles/PMC64503/",
      "pe:sourceName": "Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 (full text via PubMed Central, PMC64503)."
    },
    "pe:evidence-B5": {
      "prov:type": "pe:EmpiricalEvidence",
      "prov:label": "SC2 - ATT 2009 Lancet: meta-analysis of individual participant data from randomised trials",
      "pe:factId": "B5",
      "pe:evidenceType": "empirical",
      "pe:sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/19482214/",
      "pe:sourceName": "Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60 (abstract via PubMed, PMID 19482214)."
    },
    "pe:evidence-A1": {
      "prov:type": "pe:ComputedEvidence",
      "prov:label": "SC1 verified source count",
      "pe:factId": "A1",
      "pe:evidenceType": "computed",
      "pe:method": "count(verified sc1 citations) = 3",
      "pe:result": "3"
    },
    "pe:evidence-A2": {
      "prov:type": "pe:ComputedEvidence",
      "prov:label": "SC2 verified source count",
      "pe:factId": "A2",
      "pe:evidenceType": "computed",
      "pe:method": "count(verified sc2 citations) = 2",
      "pe:result": "2"
    },
    "pe:verdict": {
      "prov:type": "pe:Verdict",
      "prov:label": "Verdict: PROVED",
      "prov:value": "PROVED",
      "pe:doi": "10.5281/zenodo.20315066"
    }
  },
  "activity": {
    "pe:verify-B1": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B1: Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 (full text via PubMed Central, PMC64503).",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B2": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B2: Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 (full text via PubMed Central, PMC64503).",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B3": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B3: Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60 (abstract via PubMed, PMID 19482214).",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B4": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B4: Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86 (full text via PubMed Central, PMC64503).",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:verify-B5": {
      "prov:type": "pe:CitationVerification",
      "prov:label": "Verify B5: Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60 (abstract via PubMed, PMID 19482214).",
      "pe:status": "verified",
      "pe:method": "full_quote",
      "pe:fetchMode": "live"
    },
    "pe:determine-verdict": {
      "prov:type": "pe:VerdictDetermination",
      "prov:label": "Determine verdict from evidence",
      "prov:endTime": "2026-05-20"
    }
  },
  "agent": {
    "pe:proof-engine": {
      "prov:type": "prov:SoftwareAgent",
      "prov:label": "Proof Engine",
      "schema:version": "1.34.1",
      "schema:url": "https://github.com/yaniv-golan/proof-engine"
    }
  },
  "wasGeneratedBy": {
    "pe:gen-B1": {
      "prov:entity": "pe:evidence-B1",
      "prov:activity": "pe:verify-B1"
    },
    "pe:gen-B2": {
      "prov:entity": "pe:evidence-B2",
      "prov:activity": "pe:verify-B2"
    },
    "pe:gen-B3": {
      "prov:entity": "pe:evidence-B3",
      "prov:activity": "pe:verify-B3"
    },
    "pe:gen-B4": {
      "prov:entity": "pe:evidence-B4",
      "prov:activity": "pe:verify-B4"
    },
    "pe:gen-B5": {
      "prov:entity": "pe:evidence-B5",
      "prov:activity": "pe:verify-B5"
    },
    "pe:gen-verdict": {
      "prov:entity": "pe:verdict",
      "prov:activity": "pe:determine-verdict"
    }
  },
  "wasDerivedFrom": {
    "pe:deriv-A1-from-B1": {
      "prov:generatedEntity": "pe:evidence-A1",
      "prov:usedEntity": "pe:evidence-B1"
    },
    "pe:deriv-A1-from-B2": {
      "prov:generatedEntity": "pe:evidence-A1",
      "prov:usedEntity": "pe:evidence-B2"
    },
    "pe:deriv-A1-from-B3": {
      "prov:generatedEntity": "pe:evidence-A1",
      "prov:usedEntity": "pe:evidence-B3"
    },
    "pe:deriv-A2-from-B4": {
      "prov:generatedEntity": "pe:evidence-A2",
      "prov:usedEntity": "pe:evidence-B4"
    },
    "pe:deriv-A2-from-B5": {
      "prov:generatedEntity": "pe:evidence-A2",
      "prov:usedEntity": "pe:evidence-B5"
    }
  },
  "wasAttributedTo": {
    "pe:attr-verdict": {
      "prov:entity": "pe:verdict",
      "prov:agent": "pe:proof-engine"
    }
  },
  "used": {
    "pe:used-B1": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B1"
    },
    "pe:used-B2": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B2"
    },
    "pe:used-B3": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B3"
    },
    "pe:used-B4": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B4"
    },
    "pe:used-B5": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-B5"
    },
    "pe:used-A1": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-A1"
    },
    "pe:used-A2": {
      "prov:activity": "pe:determine-verdict",
      "prov:entity": "pe:evidence-A2"
    }
  }
}